Agios Pharma (AGIO) Misses Q4 EPS by 286c

Agios Pharma (NASDAQ: AGIO) reported Q4 EPS of ($4.23), $2.86 worse than the analyst estimate of ($1.37). Revenue for the quarter came in at $14.24 million versus the consensus estimate of $4.54 million.

For earnings history and earnings-related data on Agios Pharma (AGIO) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• UBS cuts KOSPI target by nearly 10% to reflect higher rates
• Deutsche Bank Upgrades Wickes Group plc (WIX:LN) to Hold